Trident Lifeline Ltd.
BBSE:TLL394.25
INR
+6.30
(+1.62%)
ISIN
INE0MKA01014
Return %
Stock
S&P 500
1Y
27.24
14.20
3Y
117.82
81.12
5Y
- -
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Shravan Harikrishna Patel
- Full Time Employees
- 46
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- North Extension Surat GU India 395003
- IPO Date
- Oct 10, 2022
- Website
- tridentlifeline.com
- Similar Companies
- Business
- Trident Lifeline Limited is a pharmaceutical company engaged in the manufacture and marketing of finished dosage pharmaceutical products. Founded in 2014 and headquartered in Surat, India, it operates through a hybrid manufacturing model producing its own export range products as well as contract manufacturing for other companies. The company’s product portfolio includes capsules, tablets, liquid orals, external preparations such as gels, mouthwash, lotions, syrups, creams, dry powders, and toothpastes. Its pharmaceutical offerings span multiple therapeutic segments including anti-bacterial, anti-diarrheal, anti-fungal, anti-malarial, anti-diabetic, dental cure, proton pump inhibitors, anti-protozoal, anti-histamine, anti-hypertensive, anti-lipidemic, anti-parasitic, multivitamins, multiminerals, nutraceuticals, and non-steroidal anti-inflammatory drugs (NSAIDs). The company also offers herbal remedies and precision-engineered injectable formulations catering to both the Indian and international markets, including countries in Africa and Latin America. Recent major developments include strategic alliances and acquisitions that expand its pharmaceutical capabilities and geographic reach. In 2023, Trident Lifeline acquired a majority stake (51%) in TLL Herbal Limited, enhancing its herbal product line. It also completed the acquisition of a 51% stake in TLL Parenterals, broadening its injectable portfolio. Additionally, in a notable collaboration with the National Institute of Pharmaceutical Education and Research Ahmedabad (NIPER-A), Trident Lifeline secured technology transfer for Vorinostat, a key drug for treating Cutaneous T-Cell Lymphoma, aiming to domestically produce and offer this rare cancer treatment in India under a "Make in India" initiative with an emphasis on affordable access. The company recently launched a new skincare brand, YES, through its subsidiary TLL Elements Private Limited. It continues to focus on expanding its product offerings and manufacturing capacity, including tablets and capsules for both general and beta-lactam antibiotics, liquids, powders, and topical products. Trident Lifeline Limited operates in seven geographic segments including India, Ghana, Kenya, Nigeria, Cameroon, Venezuela, and other international markets. It targets a broad customer base encompassing emerging markets with a focus on accessible and affordable healthcare solutions. The company maintains significant manufacturing capacity with monthly outputs of hundreds of millions of tablets and capsules and millions of liquid bottles and topical products. Its activities emphasize research-driven, safe, and effective medicines across a wide range of therapeutic needs, supported by continual investment in new product development and strategic business expansions. The company’s leadership is focused on sustainable growth and increasing its footprint in both domestic and international pharmaceutical markets.